Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Our aim was to examine the association of pretreatment tumor-infiltrating lymphocyte (TIL) count and PD-L1 levels with pathologic complete response (pCR) and assess immune marker changes following treatment in tumor specimens from the S0800 clinical trial, which randomized patients to bevacizumab + nab-paclitaxel, followed by doxorubicin/cyclophosphamide (AC) versus two control arms without bevacizumab (varying sequence of AC and nab-paclitaxel). TILs were assessed in 124 pre- and 62 posttreatment tissues (including 59 pairs). PD-L1 was assessed in 120 pre- and 43 posttreatment tissues (including 39 pairs) using the 22C3 antibody. Baseline and treatment-induced immune changes were correlated with pCR and survival using estrogen receptor (ER) and treatment-adjusted logistic and Cox regressions, respectively. At baseline, the mean TIL count was 17.4% (17% had zero TILs, 9% had ≥50% TILs). Posttreatment, mean TIL count decreased to 11% (5% had no TILs, 2% had >50% TILs). In paired samples, the mean TIL change was 15% decrease. Baseline PD-L1 was detected in 43% of cases (n = 5 in tumor cells, n = 29 stroma, n = 18 tumor + stroma). Posttreatment, PD-L1 expression was not significantly lower (33%). Higher baseline TIL count and PD-L1 positivity rate were associated with higher pCR rate even after adjustment for treatment and ER status (P = 0.018). There was no association between TIL counts, PD-L1 expression, and survival due to few events. In conclusion, TIL counts, but not PD-L1 expression, decreased significantly after treatment. Continued PD-L1 expression in some residual cancers raises the possibility that adjuvant immune checkpoint inhibitor therapy could improve survival in this patient population. Mol Cancer Ther; 17(6); 1324–31. ©2018 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Self-citationVEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140559 · Cited by 1,179 · cited 4×
“VEGF in the tumor microenvironment enhances expression of PD-1 and other inhibitory checkpoints involved in T-cell exhaustion, and this effect can be reverted by antiangiogenic agents such as bevacizumab (21).”
BackgroundInfluentialCancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042 · cited 1×
“Preclinical evidence supports that some of the antitumor activity of cytotoxic agents is mediated by antitumor immune response (18).”
BackgroundSelf-citationRimm, D. L., Han, G., Taube, J. M., Yi, E. S., Bridge, J. A., Flieder, D. B., Homer, R., West, W. W., Wu, H., Roden, A. C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0013 · Cited by 764 · cited 1×
“PD-L1 IHC PD-L1 IHCwas performed on 5-mmwhole tissue sections using the FDA-cleared 22C3 assay on the Dako Link 48 platform following the manufacturer's instructions as reported previously (24).”
MethodSelf-citation
Cited by
Li, J. J., Tsang, J. Y., & Tse, G. M. (2021) · Cancers · doi:10.3390/cancers13164233 · Cited by 180
G protein-coupled estrogen receptor in immune cells and its role in immune-related diseases
Notas, G., Kampa, M., & Castanas, E. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.579420 · Cited by 109
“Furthermore, T-lymphocytes-related apoptosis induction by GPER1 (90, 91), leads to an inability of the major immune cells infiltrating breast stroma, in primary or metastatic breast cancer to support tumor expansion (92, 93).”
BackgroundImmunotherapy in breast cancer: Current status and future directions
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2019.03.006 · Cited by 109
Reddy, S. M., Reuben, A., Barua, S., Jiang, H., Zhang, S., Wang, L., Gopalakrishnan, V., Hudgens, C. W., Tetzlaff, M. T., Reuben, J. M., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0619 · Cited by 106
Metadata
- Authors
- Pelekanou, V., Barlow, W. E., Nahleh, Z. A., Wasserman, B., Lo, Y.-C., von Wahlde, M.-K., Hayes, D., Hortobagyi, G. N., Gralow, J., Tripathy, D., Porter, P., Szekely, B., Hatzis, C., Rimm, D. L., & Pusztai, L.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2018-05-31
- Volume
- 17
- Issue
- 6
- Pages
- 1324-1331
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2794522602
- Cited by
- 91
- References
- 4
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial. https://app.cochat.ai/papers/10.1158/1535-7163.mct-17-1005
- The paper
- Pelekanou, V., Barlow, W. E., Nahleh, Z. A., Wasserman, B., Lo, Y.-C., von Wahlde, M.-K., Hayes, D., Hortobagyi, G. N., Gralow, J., Tripathy, D., Porter, P., Szekely, B., Hatzis, C., Rimm, D. L., & Pusztai, L. (2018). Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-17-1005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.